<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927832</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01515-46</org_study_id>
    <nct_id>NCT04927832</nct_id>
  </id_info>
  <brief_title>Detection of Small Fiber Neuropathies by the Non-invasive SUDOSCAN Method During Chronic Autoimmune Pathologies and / or Unexplained Pain Syndromes</brief_title>
  <acronym>SUDOCU</acronym>
  <official_title>Detection of Small Fiber Neuropathies by the Non-invasive SUDOSCAN Method During Chronic Autoimmune Pathologies and / or Unexplained Pain Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very few studies have evaluated the prevalence of small fiber neuropathy (SFN) during&#xD;
      pathologies that may be responsible for small fibers damage.&#xD;
&#xD;
      SUDOSCAN is a new rapid (2 minutes), automated, reproducible and non-invasive technology to&#xD;
      assess small fiber neuropathy by sweat function.&#xD;
&#xD;
      With quantitative and reproducible results, SUDOSCAN allows physicians to early detect and&#xD;
      follow-up peripheral neuropathy to monitor disease progression and assess treatment efficacy&#xD;
      for a better patient management.&#xD;
&#xD;
      SUDOSCAN® could allow the identification of SFN in painful patients apart from another&#xD;
      pathology already diagnosed responsible for SFN.&#xD;
&#xD;
      The purpose of the study SUDOCU is to assess the prevalence of small fiber neuropathies (SFN)&#xD;
      in patients with systemic autoimmune pathologies or unexplained pain syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients presenting diagnosis of small fiber neuropathy in chronic pathologies and / or unexplained pain syndrome</measure>
    <time_frame>53 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Autoimmune Pathologies</condition>
  <condition>Unexplained Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Patient with chronic autoimmune pathology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with unexplained pain syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SUDOSCAN and EMG (electromyogram)</intervention_name>
    <description>The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG</description>
    <arm_group_label>Patient with chronic autoimmune pathology</arm_group_label>
    <arm_group_label>Patients with unexplained pain syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient corresponding to one of the two following groups:&#xD;
&#xD;
               1. Systemic autoimmune pathology known to be complicated by small fiber&#xD;
                  neuropathies.&#xD;
&#xD;
                  The following autoimmune pathologies will be included: Lupus, Sjogren,&#xD;
                  Scleroderma, Myositis, rheumatoid arthritis, Sarcoidosis, Vasculitis of small or&#xD;
                  medium vessels&#xD;
&#xD;
               2. No conditions known to be responsible at SFN, unexplained pain symptoms&#xD;
&#xD;
          -  Aged ≥ 18 years&#xD;
&#xD;
          -  Having given free and informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic alcoholism&#xD;
&#xD;
          -  Unbalanced diabetes&#xD;
&#xD;
          -  Chemotherapies&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Vitamins B12, B1, B6 deficiencies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BENNANI</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam BENNANI</last_name>
      <phone>0413428351</phone>
      <email>m.bennani@hopital-europeen.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent CHICHE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Fiber Neuropathy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

